Who can prescribe Strattera? NP vs MD in California

If you’re exploring treatment options for ADHD, you’ve probably wondered: Can I actually get ADHD medication prescribed online? The short answer is yes—but with important caveats that depend on the type of medication, where you live, and current federal regulations.

Telehealth has transformed mental healthcare access over the past few years, making it easier than ever to connect with qualified providers from home. For adults juggling work, family, and the executive function challenges that come with ADHD, virtual care can be a game-changer. But navigating the rules around online prescriptions—especially for controlled substances—can feel overwhelming.

This guide breaks down everything you need to know about getting ADHD medication through telehealth in 2025, from federal DEA regulations to state-specific requirements, so you can make informed decisions about your care.

Understanding ADHD Medications: Controlled vs. Non-Controlled

Not all ADHD medications are treated the same under the law. The type of medication your provider recommends significantly impacts how it can be prescribed via telehealth.

Stimulant Medications (Schedule II Controlled Substances)

Common stimulant medications like Adderall, Ritalin, Vyvanse, and Concerta are classified as Schedule II controlled substances by the DEA. This classification exists because these medications have a recognized potential for abuse and dependence.

Under normal circumstances, the Ryan Haight Act of 2008 requires an in-person medical evaluation before a provider can prescribe controlled substances via telemedicine. However, pandemic-era emergency rules temporarily waived this requirement.

Current status (as of December 2025): The DEA has extended telehealth prescribing flexibilities for Schedule II-V controlled substances through December 31, 2025. This means qualified providers can still prescribe stimulant ADHD medications via video visits without a prior in-person exam—but this flexibility has an expiration date.

What happens in 2026? The DEA is reviewing proposals for permanent telehealth prescribing rules, including a potential ‘Special Registration’ pathway. A fourth extension is anticipated, but nothing is finalized yet. Patients and providers should stay informed about potential changes that could require in-person visits starting next year.

Non-Stimulant Medications (Not Controlled)

Non-stimulant ADHD medications like Strattera (atomoxetine), Qelbree (viloxazine), Intuniv (guanfacine), and Kapvay (clonidine) are not classified as controlled substances by the DEA.

This is crucial because it means federal law has never restricted telehealth prescribing of these medications. There’s no special in-person exam requirement, no Ryan Haight Act complications, and no temporary waivers to worry about. As long as your provider is licensed in your state and establishes an appropriate doctor-patient relationship via video consultation, they can prescribe non-stimulants through telehealth—now and after any DEA policy changes.

For many patients, especially those concerned about stimulant side effects, abuse potential, or the uncertainty around future telehealth rules, non-stimulants offer a viable path to treatment that’s less affected by regulatory changes.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

How Telehealth ADHD Prescribing Actually Works

Contrary to what some people assume, getting ADHD medication through telehealth isn’t as simple as filling out an online quiz. Legitimate telehealth providers follow the same rigorous diagnostic standards as in-person clinicians.

The Evaluation Process

A proper ADHD telehealth evaluation typically includes:

Comprehensive intake questionnaire: You’ll answer detailed questions about your symptoms, medical history, previous treatments, substance use history, and current medications.

Video consultation: A licensed clinician (MD, DO, or psychiatric nurse practitioner in most states) will conduct a face-to-face video interview. Expect this to last 30-60 minutes for an initial evaluation.

Symptom assessment: Providers use standardized tools based on DSM-5 criteria to evaluate whether your symptoms meet diagnostic thresholds. They’ll ask about symptoms in multiple settings (work, home, relationships) and symptom onset (ADHD typically begins in childhood, though many adults weren’t diagnosed until later).

Medical screening: The provider will screen for conditions that could contraindicate certain medications—like uncontrolled high blood pressure, heart conditions, glaucoma, or severe anxiety disorders.

Treatment planning: If diagnosed, you’ll discuss treatment options, including both medication and non-medication approaches like therapy or coaching.

What to Expect for Follow-Up Care

ADHD medication management doesn’t end with the first prescription. Responsible telehealth providers require regular follow-up:

• Initial follow-up typically occurs within 2-4 weeks to assess medication effectiveness and side effects
• Ongoing monitoring usually happens monthly, especially when starting or adjusting medications
• Symptom tracking to evaluate whether treatment is actually improving your functioning
• Coordination with other providers when appropriate, such as your primary care physician or therapist

For stimulant medications, providers must issue a new prescription each month (federal law prohibits refills on Schedule II drugs). For non-stimulants like Strattera, you can typically get 90-day supplies with refills, making ongoing management more convenient.

State-by-State Variations: What You Need to Know

While federal law sets the baseline, state regulations add another layer of complexity. Here’s what matters most in key states:

States with Special Requirements

New York: As of May 2025, New York requires an initial in-person evaluation before prescribing any controlled substance via telemedicine. This means if you’re seeking stimulant ADHD medication in NY, you’ll need to see a provider face-to-face first (or have a qualifying in-person exam from another provider). This doesn’t affect non-stimulant prescriptions like Strattera, which can still be prescribed entirely via telehealth.

Alabama: Alabama mandates that after four telehealth visits for the same condition, patients must have an in-person visit within 12 months. However, mental health services are exempt from this rule, and ADHD treatment typically qualifies for this exemption. Alabama also requires a healthcare professional to be physically present with the patient during the initial telehealth visit for controlled substance prescriptions—essentially, you can’t be completely alone at home for your first stimulant prescription.

Florida: Florida law prohibits telehealth prescribing of Schedule II medications except for specific circumstances, including treatment of psychiatric disorders. Fortunately, ADHD qualifies as a psychiatric condition, so stimulant prescriptions via telehealth are permitted. Additionally, Florida requires PDMP (Prescription Drug Monitoring Program) checks before every controlled substance prescription.

Texas: Very telehealth-friendly for mental health care. Texas allows telemedicine for behavioral health conditions without requiring in-person visits for ADHD treatment specifically. However, Texas has restrictions on what nurse practitioners and physician assistants can prescribe—they generally cannot prescribe Schedule II stimulants in outpatient settings (only in hospitals or hospice care).

New Hampshire: Recently liberalized its telehealth rules. As of August 2025, NH removed prior in-person requirements and now only requires at least an annual follow-up evaluation (which can be done via telehealth) for controlled substance prescribing.

States with Provider Flexibility

California, Illinois, Pennsylvania, and Georgia generally allow telehealth ADHD treatment without mandating in-person visits, as long as providers follow standard of care and establish proper doctor-patient relationships. California is considering legislation (AB 1503) to further clarify that telehealth exams count as prior exams for prescribing purposes.

The key takeaway: Your state matters. Reputable telehealth services like Klarity Health ensure they’re matching you with providers licensed in your state who understand and follow local regulations. Always verify your provider’s credentials and state licensure before beginning treatment.

Who Can Prescribe ADHD Medications Via Telehealth?

Not all providers have the same prescribing authority, especially for controlled substances.

Physicians (MD/DO)

Licensed physicians can prescribe all ADHD medications—stimulants and non-stimulants—via telehealth in all states, provided they comply with federal DEA requirements and state telehealth laws. They need a valid DEA registration to prescribe controlled substances.

Nurse Practitioners (NPs)

NP prescribing authority varies dramatically by state:

Full practice authority states (like California, New York, New Hampshire, Illinois): NPs can practice and prescribe independently, including Schedule II stimulants, after meeting experience requirements (typically 2,000-4,000 supervised hours).

Reduced practice states (like Florida, Pennsylvania): NPs must have a collaborative agreement with a physician but can still prescribe controlled substances with proper delegation.

Restricted practice states (like Texas, Georgia, Alabama): NPs face limitations on Schedule II prescribing. For example, Georgia NPs cannot prescribe Schedule II drugs at all, and Texas NPs can only do so in hospital or hospice settings.

For non-stimulant medications like Strattera, NPs in all states can prescribe with at least a collaborative agreement (and independently in full-practice states).

Physician Assistants (PAs)

PAs generally require a supervising physician and face similar Schedule II restrictions as NPs in their state. However, they can prescribe non-controlled ADHD medications in all states under appropriate supervision.

When choosing a telehealth provider, understanding these distinctions helps you know what to expect. Klarity Health works with both physicians and advanced practice providers, ensuring you’re matched with someone who has the appropriate credentials and authority to treat you in your state.

The Strattera Advantage: Non-Stimulant ADHD Treatment Via Telehealth

Given the regulatory complexity around stimulant prescriptions, many patients and providers are turning to non-stimulant options like Strattera (atomoxetine).

Why Strattera Makes Sense for Telehealth Patients

No DEA restrictions: Since Strattera isn’t a controlled substance, there are no special federal prescribing rules. You won’t need an in-person exam, even if DEA telehealth flexibilities expire.

Longer prescriptions: Unlike stimulants (which require monthly prescriptions with no refills), Strattera can be prescribed in 90-day supplies with multiple refills. This means fewer appointments and pharmacy visits.

No abuse potential: Strattera doesn’t produce the euphoric effects that stimulants can, and it’s not habit-forming. This makes it appropriate for patients with a history of substance use concerns.

Consistent effect: Unlike stimulants that work immediately but wear off daily, Strattera builds up in your system and provides steady symptom control 24/7. This can be ideal for patients who need consistent coverage without managing medication timing.

State flexibility: No state restricts telehealth prescribing of Strattera the way some restrict stimulants.

Who Benefits Most from Non-Stimulant Treatment?

Strattera may be particularly appropriate if you:

• Have co-occurring anxiety (stimulants can sometimes worsen anxiety)
• Experience problematic side effects from stimulants
• Have a personal or family history of substance use disorder
• Have cardiovascular concerns that make stimulants risky
• Need consistent 24-hour symptom coverage
• Want to avoid the hassle of monthly controlled substance prescriptions
• Are concerned about future DEA rule changes affecting telehealth access

What to Know About Strattera

How it works: Strattera is a selective norepinephrine reuptake inhibitor (SNRI). It increases norepinephrine levels in the brain, which helps with attention, impulse control, and hyperactivity.

Timeline: Unlike stimulants that work within an hour, Strattera typically takes 4-6 weeks to reach full effectiveness. You’ll need patience during the initial treatment period.

Dosing: Strattera is usually started at a low dose and gradually increased based on response and tolerability. Your provider will work with you to find the right dose.

Side effects: Common side effects include decreased appetite, upset stomach, nausea, dizziness, and fatigue, especially when starting. These often improve over time. Serious but rare side effects include increased blood pressure, liver problems, and (particularly in youth) increased suicidal thoughts—your provider will monitor for these.

Monitoring: While you don’t need monthly appointments like with stimulants, your provider will still want regular check-ins to assess effectiveness and side effects. Blood pressure monitoring is typically recommended.

Prescription Monitoring Programs and Safety Measures

One area that confuses many patients is Prescription Drug Monitoring Programs (PDMPs)—state databases that track controlled substance prescriptions.

What Are PDMPs and When Do They Apply?

Most states require healthcare providers to check the PDMP before prescribing controlled substances. The frequency varies:

• Every prescription: Florida, New Hampshire, Alabama
• First prescription + every 90 days: Pennsylvania, California (every 4 months)
• First prescription only: Georgia

Important: PDMP requirements apply to controlled substances only. If you’re receiving Strattera or another non-controlled medication, your provider isn’t legally required to check the PDMP (though many do as a general precaution to review your medication history).

For stimulant prescriptions, expect your provider to:

• Verify your identity thoroughly
• Check the state PDMP to see your controlled substance prescription history
• Look for potential red flags (like getting the same medication from multiple providers)
• Ask about other medications you’re taking to check for interactions

Why This Actually Protects Patients

While PDMP checks might feel intrusive, they serve important purposes:

Identify dangerous interactions: Your provider can see if you’re on other medications that could interact with ADHD meds

Prevent duplicative prescribing: Ensures you’re not inadvertently getting the same medication from multiple sources

Support coordinated care: Helps your provider understand your complete treatment picture

Combat diversion: Makes it harder for people to obtain controlled substances for illegal purposes, which protects legitimate patients’ access

Legitimate patients have nothing to fear from PDMP checks—they’re a standard part of responsible prescribing.

Cost Considerations: Insurance vs. Cash Pay

One of the advantages of telehealth is often transparent, affordable pricing. Understanding your options helps you make the best financial decision.

Insurance Coverage for Telehealth ADHD Treatment

Most insurance plans now cover telehealth visits at the same rate as in-person visits, thanks to pandemic-era policy changes that many insurers have made permanent. However, coverage specifics vary:

• Copays: Typically $10-75 per visit depending on your plan and whether you see an in-network provider
• Medication coverage: Your insurance should cover ADHD medications similarly whether prescribed via telehealth or in-person
• Prior authorization: Some plans require pre-approval for ADHD medications, particularly stimulants
• Quantity limits: Many insurers limit stimulant prescriptions to 30-day supplies

Pro tip: Verify your coverage before your first appointment. Ask about mental health visit copays and whether ADHD medications are on your plan’s formulary.

Cash-Pay Options

If you’re uninsured or prefer not to use insurance, many telehealth providers offer cash-pay options with transparent pricing. At Klarity Health, we accept both insurance and self-pay, giving you flexibility based on your situation.

Cash-pay benefits include:

• Privacy: Your ADHD treatment won’t appear on insurance records (relevant for those with career concerns)
• Simplicity: No prior authorizations, formulary restrictions, or insurance paperwork
• Predictability: You know exactly what you’ll pay upfront
• Access: No need to find in-network providers or get referrals

Medication costs also vary:

• Stimulants: Generic stimulants typically cost $30-75/month without insurance; brand names can be $200-400+
• Strattera: Generic atomoxetine costs about $30-90/month; brand-name Strattera can be $300-400+
• GoodRx and discount programs: Can significantly reduce medication costs if paying out of pocket

Red Flags: Identifying Legitimate vs. Problematic Telehealth Services

Unfortunately, the ADHD telehealth space has attracted some bad actors. High-profile investigations of companies like Cerebral and Done in 2022-2023 revealed concerning practices, including prescribing stimulants with minimal evaluation.

Signs of a Reputable Telehealth Provider

✅ Requires video consultation: Legitimate providers don’t prescribe controlled substances based solely on questionnaires or text chats

✅ Comprehensive evaluation: Expects appointments of 30+ minutes for initial assessment, uses structured diagnostic tools

✅ Licensed clinicians: Clearly identifies providers’ credentials and state licenses

✅ Discusses alternatives: Talks about both medication and non-medication treatment options

✅ Requires follow-up: Schedules regular check-ins and monitors treatment effectiveness

✅ Transparent about limitations: Explains what they can and cannot treat via telehealth, referring out when appropriate

✅ Checks credentials: Verifies your identity, reviews medical history, checks PDMP

Warning Signs of Problematic Services

🚩 Guarantees prescription: No ethical provider can promise medication before evaluating you

🚩 No video requirement: Prescribing controlled substances without video consultation violates regulations

🚩 Minimal questioning: ‘Rubber-stamp’ prescribing with cursory evaluation

🚩 No follow-up: Provides prescriptions without requiring ongoing monitoring

🚩 Refuses to coordinate care: Won’t communicate with your other healthcare providers

🚩 Unusual payment: Requests payment via cryptocurrency, gift cards, or wire transfers

🚩 Ships medication directly: Legitimate U.S. providers prescribe through licensed pharmacies, not direct shipping operations

If something feels off, trust your instincts. You deserve quality care that prioritizes your safety alongside access.

What Happens If DEA Rules Change in 2026?

The current telehealth flexibility for stimulant prescribing expires December 31, 2025. While a fourth extension is likely, it’s worth understanding potential scenarios.

Possible Outcomes

Scenario 1: Another ExtensionMost likely in the short term. The DEA and healthcare industry recognize that millions of patients now rely on telehealth for ADHD treatment, and abrupt policy changes could create significant access problems.

Scenario 2: New Permanent FrameworkThe DEA has proposed a ‘Special Registration’ system that could allow continued telehealth prescribing with additional safeguards. This might include requirements like:

• Initial in-person evaluation within 30 days of first prescription
• More frequent provider-patient check-ins
• Enhanced monitoring and reporting requirements
• Special provider certification

Scenario 3: Return to Pre-Pandemic RulesLeast likely but possible: Complete return to Ryan Haight Act requirements, mandating an in-person visit before any controlled substance prescription via telemedicine.

What This Means for Your Care

If you’re currently getting stimulant ADHD medication via telehealth:

Stay informed: Pay attention to communications from your provider about policy updates

Plan ahead: If in-person requirements are reinstated, work with your provider to coordinate local care

Consider alternatives: Non-stimulants like Strattera aren’t affected by DEA rules and provide continuity regardless of policy changes

Don’t panic: Legitimate telehealth providers are preparing for various scenarios and will help you maintain treatment access

Ask questions: Talk to your provider about their contingency plans

At Klarity Health, we’re closely monitoring these developments and committed to ensuring continuous care for our patients, whatever regulatory changes may come.

Getting Started with Telehealth ADHD Treatment

If you’re considering telehealth for ADHD, here’s how to move forward:

Step 1: Choose a Reputable Provider

Look for platforms that:

• Use licensed clinicians in your state
• Have clear pricing and policies
• Require comprehensive video evaluations
• Support coordinated care with other providers
• Have positive patient reviews and established track records

Klarity Health offers convenient access to licensed psychiatrists and psychiatric nurse practitioners across multiple states, with transparent pricing whether you use insurance or pay out of pocket. Our providers take the time for thorough evaluations and ongoing management, ensuring you get quality care that follows all applicable regulations.

Step 2: Prepare for Your Appointment

Gather information to share with your provider:

• Symptom history: When symptoms started, how they affect your daily life
• Previous treatments: What you’ve tried before (medications, therapy, other interventions)
• Medical history: Current conditions, medications, allergies
• Family history: ADHD and mental health conditions in relatives
• Documentation: Past medical records, school reports, or previous ADHD evaluations if available
• Current functioning: Specific examples of how ADHD impacts work, relationships, daily tasks

Be honest and thorough. Your provider needs accurate information to help you safely and effectively.

Step 3: Attend Your Evaluation

During your video consultation:

• Be in a quiet, private space with good lighting and stable internet
• Have your ID ready for verification
• Ask questions about treatment options, including pros/cons of different medications
• Discuss your concerns, goals, and preferences
• Take notes or ask if you can record the session (with permission)

Step 4: Start Treatment and Follow Up

If medication is prescribed:

• Fill your prescription promptly at your preferred pharmacy
• Follow dosing instructions exactly as prescribed
• Track your symptoms and side effects
• Attend follow-up appointments as scheduled
• Communicate any concerns between appointments

Step 5: Optimize Your Treatment

ADHD management isn’t just about medication:

• Consider adding therapy (CBT, ADHD coaching)
• Implement organizational strategies and routines
• Address sleep, exercise, and nutrition
• Build support systems
• Regularly reassess whether your treatment is meeting your goals

The Bottom Line

Yes, you can get ADHD medication through telehealth—both stimulants (currently, through end of 2025 under federal waivers) and non-stimulants (always, with no special restrictions). The key is working with legitimate providers who follow proper diagnostic protocols and comply with federal and state regulations.

For many adults with ADHD, telehealth removes significant barriers to treatment: no need to take time off work for appointments, no commute, and often more affordable and accessible care. The convenience factor is especially valuable for people whose ADHD symptoms make traditional in-person healthcare challenging to navigate.

If you’re concerned about the evolving regulatory landscape around stimulant prescriptions, non-stimulant medications like Strattera offer a stable, regulation-proof alternative that can be effectively managed entirely via telehealth now and in the future.

The most important thing is to get started. ADHD is highly treatable, and you don’t have to struggle with symptoms that are impacting your work, relationships, and quality of life. Whether you choose stimulant or non-stimulant medication, telehealth makes it easier than ever to connect with qualified providers who can help.

Ready to Start Your ADHD Treatment Journey?

Klarity Health makes it simple to get evaluated and treated for ADHD—entirely online, with licensed providers in your state. We offer:

✓ Fast appointments – Often available within 24-48 hours
✓ Comprehensive evaluations – Thorough diagnostic assessments, not quick questionnaires
✓ Flexible payment options – Accept insurance and offer transparent cash-pay pricing
✓ Ongoing support – Regular follow-ups to optimize your treatment
✓ Complete care – Medication management plus referrals to therapy and coaching

Our providers stay current with all state and federal regulations, ensuring you receive safe, legal, and effective care. Whether you’re seeking stimulant or non-stimulant medication, we’ll work with you to find the right treatment approach.

Don’t let ADHD symptoms continue to hold you back. Schedule your consultation with Klarity Health today and take the first step toward better focus, organization, and quality of life.

Sources

1. Drug Enforcement Administration (DEA). ‘Third Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Substances.’ Federal Register, November 2024. Reported via Fierce Healthcare: www.fiercehealthcare.com

2. McDermott Will & Emery LLP. ‘DEA Signals Extension of Telemedicine Flexibilities for Controlled Substance Prescribing for 2026.’ Legal insights, December 2025: www.mwe.com

3. Sheppard Mullin Richter & Hampton LLP. ‘Telehealth and In-Person Visits: Tracking Federal and State Updates to Pandemic-Era Telehealth Exceptions.’ National Law Review, August 15, 2025: www.sheppardhealthlaw.com

4. RxAgent. ‘The Telehealth Compliance Trap: What Every Healthcare Provider Needs to Know About Prescribing Controlled Substances.’ October 2025: www.rxagent.co

5. Medical News Today. ‘Is Strattera a controlled substance?’ Medically reviewed article, January 14, 2025: www.medicalnewstoday.com

Source:

• https://www.fiercehealthcare.com/regulatory/dea-finalizes-one-year-extension-controlled-substance-prescribing-telehealth-punts-final#:~:text=The%20Drug%20Enforcement%20Administration%20,Federal%20Register%20on%20Friday%20night
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=visit,examination%20through%20December%2031%2C%202025
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=A%20new%20rule%20posted%20on,date%20of%20December%2031%2C%202025
• https://www.fiercehealthcare.com/regulatory/dea-finalizes-one-year-extension-controlled-substance-prescribing-telehealth-punts-final#:~:text=The%20%E2%80%9CThird%20Temporary%20Extension%20of,14
• https://www.medicalnewstoday.com/articles/drugs-is-strattera-a-controlled-substance#:~:text=Strattera%20,such%20as%20mental%20health%20issues
• https://www.sheppardhealthlaw.com/2025/08/articles/telehealth/telehealth-and-in-person-visits-tracking-federal-and-state-updates-to-pandemic-era-telehealth-exceptions/#:~:text=In%20late%202024%2C%20the%20U,prescribing
• https://www.rxagent.co/blog/telehealth-compliance-trap#:~:text=The%20,False%20Hope
• https://www.techtarget.com/virtualhealthcare/news/366616019/Telehealth-prescribing-flexibility-extended-through-2025#:~:text=Image%20filo%2FDigitalVision%20Vectors%20via%20G,The
• https://natlawreview.com/article/telehealth-and-person-visits-tracking-federal-and-state-updates-pandemic-era?amp=#:~:text=Extend%20natlawreview,before%20issuing%20a%20dangerous%20drug
• https://www.rxagent.co/blog/telehealth-compliance-trap#:~:text=,specifically%20for%20chronic%20pain%20treatment